Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04392206
PHASE1

AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses

Sponsor: Houssam Farres, M.D.

View on ClinicalTrials.gov

Summary

Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.

Official title: A Phase I, Open Label Study of Allogeneic Adipose Derived Mesenchymal Stem Cells in Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2020-05-15

Completion Date

2027-06

Last Updated

2025-08-12

Healthy Volunteers

No

Interventions

DRUG

Adipose Derived Mesenchymal Stem Cells

The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution

Locations (1)

Mayo Clinic in Florida

Jacksonville, Florida, United States